| Literature DB >> 35255534 |
Hyo-In Rhyou1, Young-Hee Nam2, Hae-Sim Park3.
Abstract
Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NERD) is a unique condition characterized by aspirin/NSAID hypersensitivity, adult-onset asthma, and/or chronic rhinosinusitis with nasal polyps. Arachidonic acid metabolism dysregulation and intense eosinophilic/type 2 inflammation are central mechanisms in NERD. Studies have been conducted on various biomarkers, and urinary leukotriene E4 is considered the most available biomarker of NERD. However, the pathophysiology of NERD is heterogeneous and complex. Epithelial cells and platelets can interact with immune cells in NERD, and novel biomarkers related to these interactions have recently been investigated. We summarize emerging novel biomarkers of NERD and discuss their roles in the management of NERD.Entities:
Keywords: Aspirin; asthma; biomarkers; eosinophils; epithelial cells; hypersensitivity; leukotrienes; platelets
Year: 2022 PMID: 35255534 PMCID: PMC8914608 DOI: 10.4168/aair.2022.14.2.153
Source DB: PubMed Journal: Allergy Asthma Immunol Res ISSN: 2092-7355 Impact factor: 5.764
Fig. 1Arachidonic acid metabolism and therapeutic approach for the management of NERD. Arachidonic acid metabolism is initiated by 2 major enzymes, COX and 5-LO. 5-LO enzyme generates LTA4, which is then converted to LTC4 by LTC4 synthase. LTC4 is metabolized in the order of LTD4 and LTE4. LTC4, LTD4, and LTE4 are designated as cysLT. LTA4 can also be converted to LTB4 by LTA4 hydrolase. COX (COX-1 and COX-2) catalyzes arachidonic acid to PGG2 and subsequently PGH2, which can be further metabolized into PGI2, PGF2, PGD2, PGE2, and TXA2 by corresponding specific synthases. NERD is characterized with systemic elevations in PGD2 along with reduction in PGE2 and overproduction of cysLTs. The inhibition of the COX pathway results in the reduction in PGE2 production and excessive production of cysLTs in NERD.
COX, cyclooxygenase; LO, lipoxygenase; LT, leukotriene; cysLT, cysteinyl leukotriene; PG, prostaglandin; TX, thromboxane; NERD, nonsteroidal anti-inflammatory drug-exacerbated respiratory disease; TP, thromboxane prostanoid; DP, D-prostanoid; CRTH2, chemoattractant receptor-homologous molecule expressed on TH2 cells; HPETE, hydroperoxyeicosatetraenoic acid.
Summary of biomarkers of NERD vs. ATA
| Variables | Biomarker | Sample | Methodology | Baseline vs. ATA | Ref. | Response after ASA challenges vs. ATA | Ref. |
|---|---|---|---|---|---|---|---|
| Arachidonic acid metabolism | LTE4 | Urine | Immunoassay | ↑ |
| ↑ |
|
| Metabolomic analysis | ↑ |
| |||||
| Sputum | Immunoassay | ↑ |
| ||||
| Mass spectrometry | ↑ |
| ↑ |
| |||
| Saliva | Immunoassay | ↑ |
| ||||
| Blood | Immunoassay | ↑ |
| ↑ |
| ||
| Metabolomic analysis | ↑ |
| ↑ |
| |||
| LTE4/PGF2α | Urine | Metabolomic analysis | ↑ |
| ↑ |
| |
| Mass spectrometry | ↑ |
| |||||
| Blood | Metabolomic analysis | ↑ |
| ↑ |
| ||
| Mass spectrometry | ↑ |
| |||||
| LTB4 glucuronide | Urine | Immunoassay | ↔ |
| ↑ |
| |
| PGD2 | Sputum | Mass spectrometry | ↑ |
| ↑ |
| |
| 9α,11β-PGF2 | Blood | Mass spectrometry | ↑ |
| |||
| PGD-M | Urine | Mass spectrometry | ↑ |
| |||
| Eosinophilic inflammation | Eosinophils | Bronchial biopsy | Immunohistochemical staining | ↑ |
| ||
| Nasal fluid | Morphological count of stained slide | ↑ |
| ↑ |
| ||
| EDN | Blood | Immunoassay | ↑ |
| |||
| Mast cells | Bronchial biopsy | Morphological count | ↑ |
| |||
| Basophils | Nasal fluid | Morphological count | ↑ |
| |||
| Epithelial cells | Periostin | Blood | Immunoassay | ↑ |
| ||
| TGF-β | Blood | Immunoassay | ↑ |
| |||
| DPP10 | Blood | Immunoassay | ↑ |
| |||
| SPD | Blood | Immunoassay | ↓ |
| |||
| FCN | Blood | Immunoassay | ↑ |
| |||
| Platelets | Platelet-associated leukocytes | Blood | Flow cytometry | ↑ |
| ||
| Nasal polyp tissue | Immunohistochemistry | ↑ |
| ||||
| sP-selectin and sCD40L | Blood | Immunoassay | ↑ |
|
ASA, aspirin; ATA, aspirin-tolerant asthma; NERD, nonsteroidal anti-inflammatory drug-exacerbated respiratory disease; LTE4, leukotriene E4; PGF2α, prostaglandin F2α; LTB4, leukotriene B4; PGD2, prostaglandin D2; 9α,11β-PGF2: 9 alpha, 11 beta-prostaglandin F2; PGD-M, prostaglandin D2 metabolite; EDN, eosinophil-derived neurotoxin; TGF-β, transforming growth factor-beta; DPP10, dipeptidyl-peptidase 10; SPD, surfactant protein D; FCN, folliculin; sP-selectin, soluble P-selectin; sCD40L, soluble CD40 ligand.
Fig. 2Inflammatory pathway and therapeutic approach for the management of NERD. Various exogenous factors, such as viruses, bacteria, and environmental factors, can initiate epithelial injury and release of alarmins, IL33, IL25, and TSLP. These elevated levels of alarmins and cytokines from epithelial cells induce type 2 inflammatory responses by activating mast cells and ILC2 which are capable of activating eosinophils. Activated mast cells and eosinophils release various cytokines and chemokines that can induce mucosal inflammation and bronchoconstriction. The increased burden of platelet-associated leukocytes in NERD can further enhance the production of cysLTs, PGD2, and TXA2.
NERD, nonsteroidal anti-inflammatory drug-exacerbated respiratory disease; IL, interleukin; TSLP, thymic stromal lymphopoietin; ILC2, innate lymphoid type-2 cell; cysLT, cysteinyl leukotriene; PGD2, prostaglandin D2; TXA2, thromboxane A2; TGF, transforming growth factor; DPP10, dipeptidyl peptidase 10; SPD, surfactant protein D; LT, leukotriene; PG, prostaglandin; TX, thromboxane; INF, interferon.